139,237 results match your criteria: "Inflammatory Bowel Disease"
iScience
November 2024
Department of Gastroenterology, Peking University People's Hospital, Beijing 100044, China.
Inflammatory bowel disease (IBD) presents a range of extraintestinal manifestations, notably including oral cavity involvement. The mechanisms underlying oral-gut crosstalk in IBD are not fully understood. Exosomes, found in various body fluids such as saliva, play an unclear role in IBD that requires further exploration.
View Article and Find Full Text PDFiScience
December 2024
Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu, China.
Therap Adv Gastroenterol
January 2025
Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Inflammatory bowel diseases (IBDs), primarily encompassing ulcerative colitis and Crohn's disease, represent a challenging spectrum of disorders with a multifaceted pathogenesis. Despite the array of available treatments, a demand for novel therapeutic options persists to achieve remission in a broader patient population. Research findings indicate that relying solely on a single biologic drug may limit future treatment choices, prompting consideration for a more suitable shift from step-up to top-down strategies in certain cases.
View Article and Find Full Text PDFTherap Adv Gastroenterol
January 2025
F. Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, West Hollywood 90048, CA, USAKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Therap Adv Gastroenterol
January 2025
Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, China.
Therap Adv Gastroenterol
January 2025
Division of Gastroenterology, Department of Medicine, Siriraj Hospital, Mahidol University, 2 Wanglang Road, Siriraj, Bangkok Noi, Bangkok 10700, Thailand.
Background: The association between inflammatory bowel disease (IBD) activity and poor sleep quality is reported. However, most research subjectively investigated this issue and lacked long-term follow-up.
Objectives: Our study aimed to investigate the prevalence of sleep disturbance in IBD patients across disease activity and evaluate the long-term correlation between disease activity, sleep quality, and quality of life.
J Crohns Colitis
January 2025
Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Background And Aims: Limited data are available on long-term disease outcomes in elderly-onset (EO) inflammatory bowel diseases (IBD) from well-defined population-based cohorts. Our aim was to analyze incidence, disease course, surgery rates and therapeutic strategies of EO IBD in a prospective population-based cohort.
Methods: EO IBD was defined if diagnosis was established at ≥60years of age.
Acta Paediatr
January 2025
Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland.
Aim: We evaluated the frequency and severity of COVID-19, and vaccination status, in children with different forms of inflammatory bowel disease (IBD).
Methods: This was a prospective, observational cohort study that used a questionnaire to gather data on the patients' vaccination doses, medication and disease activity. Disease flare was defined as worsening IBD symptoms and changes in medication.
Ann Med
December 2025
Department of Gastroenterology, Oslo University Hospital.
Background: The benefit of therapeutic drug monitoring (TDM) and implementation of recommendations from the Selection of Therapeutic Targets in Inflammatory Bowel Disease (IBD, STRIDE) are discussed in the IBD community. We report real-world data in ulcerative colitis patients receiving first-line tumour necrosis factor inhibitor (TNFi) treatment followed by TDM, and assess how implementation of the STRIDE II recommendations might affect clinical practice.
Methods: Adult, biologically naïve UC patients starting TNFi between 2014 and 2021 at Oslo University Hospital were included in a medical chart review study, and data were collected at three and twelve months after the start of treatment.
United European Gastroenterol J
January 2025
Division of Gastroenterology and Gastrointestinal Endoscopy, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy.
United European Gastroenterol J
January 2025
Department of Gastroenterology, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris APHP, Paris, France.
Aliment Pharmacol Ther
January 2025
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Saudi J Gastroenterol
January 2025
Department of Gastroenterology and Hepatology, King Fahad Medical City, Riyadh, Saudi Arabia.
Background: Approximately 25% of individuals with inflammatory bowel disease (IBD) concurrently experience immune-mediated inflammatory diseases (IMIDs), while the overall prevalence of these conditions in the general population is 5-7%. Individuals with IBD and concurrent IMIDs tend to have a more aggressive disease profile. We aimed to assess the prevalence of coexisting autoimmune disorders among patients with IBD and their association with inflammatory bowel disease type.
View Article and Find Full Text PDFSaudi J Gastroenterol
January 2025
Department of Gastroenterology, Ankara City Hospital, Ankara, Turkey.
Background: To compare the long-term safety and efficacy of Adalimumab (ADA) and Infliximab (IFX) agents in biologic-naive patients with Ulcerative colitis (UC).
Methods: The key focus was on specific outcomes such as the requirement of hospitalization due to UC, colectomy, steroid administration, and severe infections that led to the discontinuation of therapy.
Results: Anti-TNF treatment was initiated in 208 of the 475 patients with ulcerative colitis.
Aliment Pharmacol Ther
January 2025
Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Background: Up to 30% of patients with Crohn's disease (CD) will experience a mild disease course. However, there is no consensus definition for mild CD.
Aim: To examine the Simple Endoscopic Score for Crohn's disease (SES-CD) thresholds best associated with low likelihood of long-term disease progression.
Intest Res
January 2025
Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Clinical guidelines typically endorse conventional therapies such as 5-aminosalicylic acid (5-ASA) as the mainstay of ulcerative colitis management. However, the degree of adoption and application of guideline recommendations by physicians within Asia remains unclear. This study aims to understand the prescribing patterns of 5-ASA and implementation of current guideline recommendations across Asian clinical practice.
View Article and Find Full Text PDFInflammopharmacology
January 2025
General Surgery Department, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China.
Background: Ulcerative colitis (UC) is a significant inflammatory bowel disease (IBD) that typically arises from chronic inflammation of the intestinal tract. Report suggest that anti-inflammatory drug plays a crucial role in the protection of UC. The recent study demonstrated that columbianadin has a protective effect against UC induced by dextran sulfate sodium (DSS) in rats through the modulation of HO-1/Nrf2 and TLR4-NF-κB signaling pathways.
View Article and Find Full Text PDFDig Liver Dis
January 2025
College of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou City, Sichuan Province, People's Republic of China. Electronic address:
Am J Chin Med
January 2025
Department of Anorectal, The First Affiliated Hospital of Heilongjiang, University of Chinese Medicine Harbin, P. R. China.
Ulcerative colitis (UC), one among other refractory diseases worldwide, has shown an increasing trend of progression to colorectal cancer in recent years. In the treatment of UC, traditional Chinese medicine has demonstrated good efficacy, with a high cure rate, fewer adverse effects, great improvement in the quality of patient survival, and reduction in the tendency of cancerous transformation. It shows promise as a complementary and alternative therapy.
View Article and Find Full Text PDFClin Gastroenterol Hepatol
January 2025
Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN, USA. Electronic address:
Cell Mol Gastroenterol Hepatol
January 2025
Division of Biomedical Sciences, School of Medicine, University of California Riverside, Riverside, California, USA. Electronic address:
Background: Coronavirus disease (COVID-19), caused by SARS-CoV-2, triggered a global pandemic with severe medical and socioeconomic consequences. While fatality rates are higher among the elderly and those with underlying comorbidities, host factors that promote susceptibility to SARS-CoV-2 infection and severe disease are poorly understood. Although individuals with certain autoimmune/inflammatory disorders show increased susceptibility to viral infections, there is incomplete knowledge of SARS-CoV-2 susceptibility in these diseases.
View Article and Find Full Text PDFInflamm Bowel Dis
January 2025
Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Background: Tumor necrosis factor (TNF) is a pleiotropic cytokine that plays a critical role in the pathogenesis of immune-mediated diseases including inflammatory bowel disease (IBD). The stability of its mRNA transcript, determined in part by destabilizing sequences in its AAUU repeats (ARE) gene region, is an important regulator of its tissue and systemic levels. A deletion in the ARE region of the gene resulted in IBD and arthritis in mice and pigs, supporting a critical role for the cytokine in human IBD and several human arthritides.
View Article and Find Full Text PDFInflamm Bowel Dis
January 2025
Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, 9713GZ, Groningen, The Netherlands.
Background: Inflammatory bowel disease (IBD) is often diagnosed in young adults, and therefore frequently coincides with pregnancy. Patients may require surgery that includes (temporary) stoma placement. Literature on the occurrence of stoma-complications during pregnancy and the effect on pregnancy outcomes is limited.
View Article and Find Full Text PDFJ Crohns Colitis
January 2025
Enveda., 5700 Flatiron Parkway, Boulder, CO, 80301, USA.
Background: Inflammatory Bowel Disease (IBD), comprising Crohn's Disease (CD) and Ulcerative Colitis (UC), is a complex condition with diverse manifestations; recent advances in multi-omics technologies are helping researchers unravel its molecular characteristics to develop targeted treatments.
Objective: In this work, we explored one of the largest multi-omics cohorts in Inflammatory Bowel Disease, the Study of a Prospective Adult Research Cohort (SPARC IBD), with the goal of identifying predictive biomarkers for CD and UC and elucidating patient subtypes.
Design: We analyzed genomics, transcriptomics (gut biopsy samples), and proteomics (blood plasma) from hundreds of patients from SPARC IBD.
Am J Health Syst Pharm
January 2025
Pfizer Inc., city/state, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDF